Document is current
Any future updates will be listed below
-
Authors
Lavrichenko, Ksenia
Engdal, Emilie Sofie
Marvig, Rasmus L.
Jemt, Anders
Vignes, Jone Marius
Almusa, Henrikki
Saether, Kristine Bilgrav
Briem, Eiríkur
Caceres, Eva
Elvarsdóttir, Edda María
Gíslason, Magnús Halldór
Haanpää, Maria K.
Henmyr, Viktor
Hotakainen, Ronja
Kaasinen, Eevi
Kanninga, Roan
Khan, Sofia
Lie-Nielsen, Mary Gertrude
Madsen, Majbritt Busk
Mähler, Niklas
Maqbool, Khurram
Neethiraj, Ramprasad
Nyrén, Karl
Paavola, Minna
Pruisscher, Peter
Sheng, Ying
Singh, Ashish Kumar
Srivastava, Aashish
Stautland, Thomas K.
Andreasen, Daniel T.
de Boer, Esmee ten Berk
Vang, Søren
Wirta, Valtteri
Bagger, Frederik Otzen
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 16 October 2024
Accepted: 29 August 2025
First Online: 17 October 2025
Declarations
:
: Not applicable.
: Not applicable.
: In the past 3 years, F.O.B. has received compensation from AstraZeneca and is a founder and real owner of Fobinf ApS, advising Imunitrack ApS owned by Eli Lilly, HERVolution ApS, Novo Nordisk A/S and Aïda Oncology ApS. E.K. was at the time of submission employed at Blueprint Genetics Oy.
